Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. BioXcel Therapeutics Inc shares valued at $58 were sold by O’Neill Vincent on Dec 16 ’24. At $0.35 per share, O’Neill Vincent sold 165 shares. The insider’s holdings dropped to 19,957 shares worth approximately $7184.5199999999995 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Mehta Vimal sold 3,117 shares, netting a total of over 1,131 in proceeds. Following the sale of shares at $0.36 each, the insider now holds 59,605 shares.
Before that, Steinhart Richard I had sold 577 shares from its account. In a trade valued at $207, the Chief Financial Officer traded BioXcel Therapeutics Inc shares for $0.36 each. Upon closing the transaction, the insider’s holdings decreased to 577 shares, worth approximately $7535.5199999999995.
As published in a research note from UBS on February 21, 2024, BioXcel Therapeutics Inc [BTAI] has been rated down from a Buy to a Neutral and the price target has been revised to $4 from $9. Analysts at Mizuho downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid August. As of July 17, 2023, Guggenheim has decreased its “Buy” rating to a “Neutral” for BTAI. Earlier on March 10, 2023, Jefferies downgraded its rating. Their new recommendation was “a Hold” for BTAI stock which previously was a “a Buy”.
Analyzing BTAI Stock Performance
During the last five days, there has been a drop of approximately -17.59%. Over the course of the year, BioXcel Therapeutics Inc shares have dropped approximately -87.96%. Shares of the company reached a 52-week high of $4.1700 on 02/06/24 and a 52-week low of $0.3450 on 12/16/24. A 50-day SMA is recorded $0.5444, while a 200-day SMA reached $1.3230. Nevertheless, trading volume fell to 1.2 million shares from 0.53 million shares the previous day.
Support And Resistance Levels for BioXcel Therapeutics Inc (BTAI)
According to the 24-hour chart, there is a support level at 0.3372, which, if violated, would cause prices to drop to 0.3192. In the upper region, resistance lies at 0.3860. The next price resistance is at 0.4168. RSI (Relative Strength Index) is 32.82 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0275, which suggests the price will decrease in the coming days. Percent R is at 95.18%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
